|
Updates in Melanoma: A Focus on Neoadjuvant Approaches |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
The Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Ambulatory Care Models |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
The Spectrum of End-of-Life Care |
0.75 |
06/30/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Psychotherapeutic Strategies and Pharmacotherapy Options for Addressing Distress in Cancer Patients |
0.75 |
08/04/2022 - 12:00am to 08/04/2025 - 12:00am |
|
Updates to the Management of Cervical Cancer |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Venous Thromboembolism Management in Malignancy |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Financial Toxicity of Cancer Care |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Remembrance and Renewal: A Holistic Self-Care Program for Oncology Clinicians |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Review of Oral Targeted Therapies in Acute Myeloid Leukemia |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Hereditary Cancer Syndromes: MSK CATCH Program (Comprehensive Assessment, Treatment, and Prevention of Cancers with Hereditary Dispositions) |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
NCCN Guidelines® Insights - Multiple Myeloma, Version 1.2025 |
1.00 |
05/10/2025 - 12:00am to 05/10/2026 - 12:00am |
|
Archived NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease |
1.00 |
05/06/2025 - 12:00am to 04/30/2026 - 12:00am |
Facebook
Twitter
LinkedIn
Forward